Fremanezumab-vfrm Injection
Fremanezumab-vfrm is a monoclonal antibody injection used to prevent migraines in adults and episodic migraines in certain children and teens.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
📖 Fremanezumab-vfrm Injection: Patient Information Guide
A plain-language walkthrough of Fremanezumab-vfrm Injection — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.
🎯What it's used for▾
Fremanezumab-vfrm (Ajovy) is a preventive migraine medication — it is used regularly to reduce how often migraines occur, not to treat a migraine that has already started.
- Ajovy is approved for the preventive treatment of migraine in adults
- Ajovy is approved for the preventive treatment of episodic migraine in pediatric patients ages 6 to 17 who weigh 45 kg (about 99 lbs) or more
- Ajovy is not approved for children under age 6, children weighing less than 45 kg, or for the prevention of chronic migraine in pediatric patients
⚙️How it works▾
Fremanezumab-vfrm is a humanized monoclonal antibody — a precision-engineered protein — that targets calcitonin gene-related peptide (CGRP). CGRP is a signaling molecule in the nervous system that is believed to play a central role in triggering migraines. By binding directly to CGRP and blocking it from attaching to its receptor, fremanezumab-vfrm helps interrupt the process that leads to migraine attacks.
Because it is a large protein molecule, the body does not process it through the liver's usual drug-metabolism pathway (cytochrome P450 enzymes). Instead, it is gradually broken down by normal protein-digesting processes, the same way the body handles other proteins.
💊How it's taken▾
Ajovy is given as a subcutaneous injection (a shot just under the skin) into the abdomen, thigh, or upper arm. Adults have two scheduling options — a monthly injection or a quarterly (every three months) schedule given as three consecutive injections at one visit. Pediatric patients ages 6–17 who qualify use the monthly schedule only. If a dose is missed, give it as soon as possible and resume your schedule from that date.
- Remove Ajovy from the refrigerator and let it sit at room temperature for 30 minutes before injecting
- Do not use the medication if it has been unrefrigerated for 7 days or more
- Do not inject at the same site as another injectable drug at the same visit
- Children ages 6–12 must have the injection given by a healthcare provider or adult caregiver; teens 13 and older may self-inject after proper training
🤒Side effects — in detail▾
The most common side effect of Ajovy is injection site reactions — such as pain, redness, or firmness where the shot was given.
- Injection site pain, redness, or hardness
- Constipation (which can occasionally become severe)
- Rash, itching, or hives (signs of a hypersensitivity reaction)
More serious reactions — including severe allergic reactions (anaphylaxis, angioedema), severe constipation requiring hospitalization, new or worsening high blood pressure, and Raynaud's phenomenon — have been reported. Contact your doctor or seek emergency care if any of these occur.
⚠️Warnings & precautions▾
- Serious allergic reactions: Anaphylaxis and angioedema (severe swelling) have been reported, sometimes hours to a month after a dose. Seek emergency help immediately if you have trouble breathing, throat or face swelling, or a severe rash.
- Severe constipation: In some patients, constipation has been serious enough to require hospitalization or surgery. The risk may be higher if you take other medications that slow digestion. Tell your doctor about any new or worsening constipation.
- High blood pressure: New or worsening high blood pressure has occurred, most often within the first week of treatment. Your doctor should monitor your blood pressure during treatment.
- Raynaud's phenomenon: Some patients developed this condition — causing fingers or toes to turn white or blue and become painful — sometimes many weeks into treatment. In most reported cases, stopping Ajovy resolved symptoms. Tell your doctor right away if you notice these signs.
🔀What it interacts with▾
Ajovy has a low potential for drug interactions because it is not processed by the liver's cytochrome P450 enzyme system, which handles many common medications. However, a few situations are worth noting:
- Medications that slow gut motility (such as certain opioid pain relievers or anticholinergic drugs) — combining these with Ajovy may increase the risk of severe constipation
- Common migraine treatments (pain relievers, triptans, ergots) — these do not appear to affect how Ajovy works in the body, based on pharmacokinetic modeling
This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.
📋Before taking it▾
- Serious allergy to fremanezumab-vfrm or its ingredients: Ajovy is contraindicated if you have had a serious hypersensitivity reaction to it — do not use it
- History of constipation or use of gut-slowing medications: Your risk of serious constipation may be higher — discuss with your doctor
- High blood pressure or risk factors for it: Ajovy can cause new or worsening high blood pressure — your doctor should monitor you
- Raynaud's phenomenon: If you have a history of this condition, tell your doctor — Ajovy may worsen it, and you should be monitored closely
- Pregnancy: There are no adequate human data on safety during pregnancy. Ajovy stays in the body for a long time (half-life ~31 days). Discuss the risks and benefits with your doctor. A pregnancy registry is available at www.tevamigrainepregnancyregistry.com or 1-833-927-2605.
- Breastfeeding: It is not known whether fremanezumab-vfrm passes into breast milk. Discuss with your doctor before using Ajovy while breastfeeding.
- Children under 6 or weighing less than 45 kg: Ajovy is not approved for these patients
- Severe liver impairment: The effects of Ajovy have not been fully studied in patients with severe liver disease — tell your doctor if this applies to you
- Older adults (65 and over): Clinical studies did not include enough older patients to determine if they respond differently — use with the same cautions as any adult
📡Pharmacodynamics — effects in the body▾
Fremanezumab-vfrm blocks calcitonin gene-related peptide (CGRP) from binding to its receptor. CGRP is thought to be a key driver of migraine attacks. By preventing CGRP from attaching to the receptor, the medication helps reduce the frequency of migraines. The exact chain of events between blocking CGRP and the clinical benefit is not fully understood.
🔬Pharmacokinetics — how your body processes it▾
After a subcutaneous injection, fremanezumab-vfrm is gradually absorbed, with peak blood levels reached in about 5 to 7 days. It has a long half-life of approximately 31 days, meaning it takes about a month for half of the drug to leave your system. The medication distributes minimally outside the bloodstream and is broken down by normal protein-digesting enzymes into small peptides and amino acids — not by liver enzymes. Steady, stable blood levels are reached after approximately 6 months of regular dosing. In children and teens weighing 45 kg or more, monthly dosing produces similar drug exposures as in adults.
📦How to store it▾
Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original outer carton to protect from light. refrigerator, AJOVY must be used within 7 days or discarded. stored at room temperature, do not place back in the refrigerator.
📄 Written from Fremanezumab-vfrm Injection’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →
🩺 Pharmacist Counseling Corner
Quick, plain-English answers to the questions patients ask most about Fremanezumab-vfrm Injection — the kind of thing our pharmacy team would talk through with you at the counter.
What exactly does Ajovy do — does it stop a migraine or prevent one? ▾
Can I give myself the injection at home, or do I need to go to a clinic? ▾
What should I watch out for after my injection? ▾
I take other migraine medications. Can I keep using them with Ajovy? ▾
Is it safe to use Ajovy if I'm pregnant or trying to get pregnant? ▾
What should I do if I miss a dose? ▾
Is Fremanezumab-vfrm Injection available over the counter? ▾
When was Fremanezumab-vfrm Injection first available? ▾
💬 Answers drafted from Fremanezumab-vfrm Injection’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →
🧰 Keep exploring
💊 How Fremanezumab-vfrm Injection comes
Fremanezumab-vfrm Injection is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Injection
How this form is used
- Ajovy is used for the preventive treatment of migraine in adults
- Ajovy is used for the preventive treatment of episodic migraine in pediatric patients ages 6 to 17 who weigh 45 kg or more
- Ajovy is not approved for pediatric patients weighing less than 45 kg or for the preventive treatment of chronic migraine in pediatric patients
- Ajovy is given as a subcutaneous (under the skin) injection only — into the abdomen, thigh, or upper arm in areas that are not tender, bruised, red, or firm
- Ajovy should be removed from the refrigerator and allowed to sit at room temperature for 30 minutes before use — do not warm it with hot water or a microwave, and do not use it if it has been at room temperature for 7 days or longer
- For the quarterly schedule, Ajovy is given as three consecutive injections at the same administration visit; for multiple injections, you may use the same body site but not the exact same spot as the previous injection
- Ajovy should not be injected at the same site as another injectable medication at the same time; in children ages 6–12, a healthcare provider or adult caregiver must administer the injection
📊 Fremanezumab-vfrm Injection across the U.S. market
How Fremanezumab-vfrm Injection appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
📈 How widely Fremanezumab-vfrm Injection is used
A general measure of how commonly Fremanezumab-vfrm Injection is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Fremanezumab-vfrm Injection is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Fremanezumab-vfrm Injection prescribed? Of the 1,596 medications we measure, Fremanezumab-vfrm Injection ranks #388 by Medicaid prescriptions — more than 76% of them.
Utilization by Fremanezumab-vfrm Injection product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
1.5 ML fremanezumab-vfrm 150 MG/ML Auto-Injector Most dispensed
Summed across the 2 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2287903
1.5 ML fremanezumab-vfrm 150 MG/ML Prefilled Syringe
Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2056695
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Fremanezumab-vfrm Injection, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 3 of 5 listed Fremanezumab-vfrm Injection NDCs with Medicaid activity.
🔍 Compare Fremanezumab-vfrm Injection products
A representative set of FDA-listed product records for Fremanezumab-vfrm Injection — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 225 mg/1.5 mL | Subcutaneous | Teva Pharmaceuticals USA, Inc. × 6 listings | BLA | View NDC → |
Showing 6 of 6 products — FDA National Drug Code Directory. See every product, package size and price: browse all 6 Fremanezumab-vfrm Injection NDCs →
📈 What people report — real-world data (FDA FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Fremanezumab-vfrm Injection — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Fremanezumab-vfrm Injection in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
🏛️ The road to your pharmacy
How Fremanezumab-vfrm Injection went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
🚨 Recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
Source: openFDA drug enforcement (recall) reports.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 2056691 2 dose forms · 2 strengths
-
Dose form (SCDF) Auto-Injector RxCUI 2287902In current FDA listingsClinical drug / strength (SCD) 1.5 ML fremanezumab-vfrm 150 MG/MLRxCUI 2287903 -
Dose form (SCDF) Prefilled Syringe RxCUI 2056694No current FDA listingClinical drug / strength (SCD) 1.5 ML fremanezumab-vfrm 150 MG/MLRxCUI 2056695
Look up RxCUI 2056691 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
📦 Supply & shortage status
Whether Fremanezumab-vfrm Injection is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
🏷️ Sold under these brand names
🏭 Manufacturers & labelers
RxNorm drug class
Fremanezumab-vfrm Injection belongs to the Calcitonin gene-related peptide (CGRP) antagonists class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
🔬 Where this comes from
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How we combine label and product data
HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 1 FDA-filed SPL label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.
Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. Teva Pharmaceuticals USA, Inc. is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.
This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.